The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.
To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg \& 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
16
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States
safety of selegiline
pharmacokinetic assessment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.